The combination of PPARγ ligands with existing chemotherapy is reported to be beneficial for cancer prevention and therapy [4–7], and a novel combination with greater clinical efficacy against advanced refractory tumors including metastatic CRC (mCRC) is needed. This evidence concerns the gene PPARG and cancer.